Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 168

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

A randomized trial of maintenance interferon following high‐dose chemotherapy in multiple myeloma: long‐term follow‐up results

Open access
Cunningham, Dadvid, Powles, Ray, Malpas, James, Raje, Noopur, Milan, Sarah, Viner, Christine, Montes, Anna, Hickish, Tamas, Nicolson, Marianne, Johnson, Paul, Treleaven, Jennifer, Raymond, Julian, Gore, Martin · 1998 · British Journal of Haematology

Abstract

High‐dose chemotherapy (melphalan) with autologous marrow stem cell support (AMSCS) results in high response rates in multiple myeloma (MM), with up to 50% of patients achieving complete remission. However, these remissions are generally not durable. As the cytokine interferon alpha has been shown to prolong partial response following conventional chemotherapy, this trial was conducted to evaluate its role following high‐dose chemotherapy. 85 patients were randomly assigned to maintenance treatment with interferon alpha, 3 × 10 6 units/m 2 subcutaneously three times weekly until relapse or no further treatment following recovery from high‐dose chemotherapy (melphalan 140–200 mg/m 2 or busulphan 16 mg/kg) combined with AMSCS. At 5.8 years following the accrual of the last patient in this trial, 38 patients had died, 17 in the interferon arm and 21 in the control arm. The median progression‐free survival (PFS) in the 42 patients randomized to interferon alpha was 46 months versus 27 months in the controls. Both overall survival and PFS, which were highly significant at median follow‐up of 52 months, have now ceased to be significant, because most patients have ultimately succumbed to their disease. Interferon was tolerated by the majority of patients with very good compliance. Toxicity consisted mainly of flu‐like symptoms and malaise which were usually self‐limiting. The results of such a pilot study should be carefully interpreted and the benefits of interferon should be confirmed in larger multi‐centre studies in the setting of minimal residual disease following autologous transplantation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2141.1998.00795.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 168

Metadata

Authors
Cunningham, D., Powles, R., Malpas, J., Raje, N., Milan, S., Viner, C., Montes, A., Hickish, T., Nicolson, M., Johnson, P., Treleaven, J., Raymond, J., & Gore, M.
Venue
British Journal of Haematology
Publisher
Wiley
Published
1998-07
Volume
102
Issue
2
Pages
495-502
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2032734113
Cited by
168
References
1
FWCI
7.31
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized trial of maintenance interferon following high‐dose chemotherapy in multiple myeloma: long‐term follow‐up results. https://app.cochat.ai/papers/10.1046/j.1365-2141.1998.00795.x
The paper
Cunningham, D., Powles, R., Malpas, J., Raje, N., Milan, S., Viner, C., Montes, A., Hickish, T., Nicolson, M., Johnson, P., Treleaven, J., Raymond, J., & Gore, M. (1998). A randomized trial of maintenance interferon following high‐dose chemotherapy in multiple myeloma: long‐term follow‐up results. British Journal of Haematology. https://doi.org/10.1046/j.1365-2141.1998.00795.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.